50 results
F-1
IINN
Inspira Technologies Oxy B.H.N. Ltd
9 May 24
Registration statement (foreign)
5:02pm
or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our products, and all … plans to continue to invest in research and development to develop technology for new products;
our ability to maintain our relationships with suppliers
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
10 Apr 24
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
8:50am
also encounter bacterial resistance and limited efficacy.
The next major research and development milestone in our collaboration with Ennocure involves
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
3 Apr 24
Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb
8:56am
statements. For example, the Company is using forward-looking statements when it discusses the aims of the research and development into various
424B5
IINN
Inspira Technologies Oxy B.H.N. Ltd
1 Apr 24
Prospectus supplement for primary offering
4:01pm
by reference herein and therein, before making an investment decision.
We are a specialty medical device company engaged in the research, development, manufacturing … for general corporate purposes, which include financing our research and development, including human observational studies, system engineering and other
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
25 Mar 24
Inspira™ Technologies Reports Full Year 2023 Financial Results
9:27am
,
Year ended
December 31,
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Other expenses (income … , from US$14,893,000 in the same period of 2022. The decrease was mainly attributable to a decline in share-based compensation.
Research
6-K
EX-99.1
5tj7m
18 Mar 24
Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets
7:08am
424B5
6ja t1sfnl4ar6
28 Dec 23
Prospectus supplement for primary offering
9:28am
6-K
EX-99.1
j2pq b6n6yel848j
26 Dec 23
Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024
4:01pm
6-K
EX-99.1
sz3yl34
22 Nov 23
Notice of Annual General Meeting of Shareholders
4:01pm
6-K
EX-99.1
7g4pd53rk4fitnj
16 Nov 23
Inspira™ Technologies Reports Third Quarter 2023 Financial Results
9:27am
6-K
EX-99.1
6bz0o9cx7u38p9vmi67
10 Oct 23
Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP
5:02pm
POS AM
7du vcwepr
10 Oct 23
Prospectus update (post-effective amendment)
5:00pm
6-K
EX-99.1
8hwhf4zh0rjo
2 Oct 23
Interim Condensed Financial Statements
4:01pm
6-K
EX-99.2
t9zuzyyrcj kldo
2 Oct 23
Interim Condensed Financial Statements
4:01pm
6-K
EX-99.1
4uq9fohyodlkjd
10 Aug 23
Inspira™ Technologies Reports Second Quarter 2023 Financial Results
9:21am
6-K
EX-99.1
ylw433vh
18 May 23
Inspira™ Technologies Reports First Quarter 2023 Financial Results
4:01pm
20-F/A
nev6pcp2
19 Apr 23
Annual report (foreign) (amended)
5:42pm
424B5
o9qov1r1id to4hd0b
4 Apr 23
Prospectus supplement for primary offering
4:19pm
6-K
EX-99.1
62ehug iw5g8p
4 Apr 23
Inspira™ Technologies Reports Fourth Quarter 2022 and Full Year Financial Results
9:30am